
Performance · Recovery · Longevity
Catalogue
Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).
Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.
Tesamorelin 2mg (UPA Platinum)
|
Category: |
Muscle / GH / Performance |
|
SKU: |
TRW-TESA |
|
Price: |
R 400.00 |
|
{{variant.name}}:
|
{{opt.name}}
{{opt.name}}
|
TEST RUN WELLNESS TESAMORELIN 2 | Tesamorelin 2mg Self-Mix Vial
Tesamorelin 2 (Tesamorelin 2mg) – The gold standard for visceral (deep belly) fat loss and body recomposition. Enhances metabolism, improves muscle tone, and boosts IGF-1 levels. GHRH Platinum Series.
Product Overview
Tesamorelin 2 is a Tesamorelin 2mg self-mix vial.
Tesamorelin is a synthetic 44-amino-acid polypeptide analogue of human growth hormone-releasing hormone (GHRH). It is modified by the addition of a trans-3-hexenoyl moiety at the N-terminus (Tyr1), which protects the peptide from cleavage by dipeptidyl peptidase IV (DPP-4) and significantly prolongs its half-life in circulation.
This structural modification enables once-daily dosing and allows tesamorelin to retain full biological activity at the GHRH receptor.
How Tesamorelin Works: GHRH Receptor Agonist Pathway
Tesamorelin binds to and stimulates human GHRH receptors with similar potency to endogenous GHRH.
Upon binding to GHRH receptors on somatotroph cells in the anterior pituitary, it initiates intracellular signaling that stimulates the synthesis and pulsatile release of endogenous growth hormone (GH). The resulting GH secretion subsequently increases IGF-1 and IGFBP-3 levels.
Unlike exogenous GH administration, which bypasses the body's natural feedback mechanisms, tesamorelin preserves endogenous GH inhibitory feedback on pituitary GH secretion, which is thought to explain its more favourable safety profile relative to recombinant human GH.
In clinical pharmacokinetic studies, once-daily short-term treatment with tesamorelin augmented basal and pulsatile GH secretion. IGF-1 levels increased by 181 ± 22 μg/liter (P < 0.0001) in healthy men, and by 81.0% in patients with HIV, compared to a 5.0% decrease in the placebo group (P < 0.001).
Body Recomposition Benefits
Tesamorelin is the only FDA-approved medication specifically indicated for the reduction of excess visceral abdominal fat in HIV-infected adult patients with lipodystrophy.
It is distinguished by its ability to selectively target visceral adipose tissue (VAT) without significant effects on subcutaneous adipose tissue.
A recent meta-analysis of randomized controlled trials demonstrated that tesamorelin was associated with significant reductions in visceral adipose tissue (MD = -27.71 cm², 95% CI [-38.37, -17.06]; P < 0.001), trunk fat (MD = -1.18 kg), limb fat (MD = -0.22 kg), hepatic fat percentage (MD = -4.28%), and waist circumference (MD = -1.61 cm), alongside a significant increase in lean body mass (MD = +1.42 kg, 95% CI [1.13, 1.71]; P < 0.001).
Importantly, no significant reductions in subcutaneous adipose tissue or BMI were observed, underscoring its selective mechanism of action.
Beyond fat reduction, tesamorelin has been shown to improve muscle quality.
A study found that 26 weeks of tesamorelin was associated with significantly greater increases in muscle density (less muscle fat) across four truncal muscle groups compared to placebo.
These findings support tesamorelin as a metabolically favourable agent for body recomposition, particularly for individuals with disproportionate visceral fat accumulation.
Titration Protocol
Tesamorelin is administered via subcutaneous injection into the abdomen, rotating injection sites to reduce the risk of injection site reactions.
The standard FDA-approved dose is 2 mg injected subcutaneously once daily. In clinical trials, the 2 mg daily dose demonstrated a superior effect on visceral adipose tissue reduction compared to the 1 mg dose.
A standard titration schedule is as follows:
· Week 1–2: 2 mg once daily — starting dose, establishes baseline tolerability
· Week 3+: 2 mg once daily — maintenance dose for the duration of the treatment cycle
· Cycle completion: 26–52 weeks, based on clinical trial durations
The injection should be administered at approximately the same time each day. In clinical studies, tesamorelin was administered as 2 mg subcutaneously daily for 26 weeks, with effects persisting for up to 1 year of therapy.
Dose escalation should only proceed if the current dose is well tolerated.
Combination Therapy
Tesamorelin is increasingly used in combination with GLP-1 receptor agonists for a targeted approach to visceral fat reduction that preserves lean mass.
A first-of-its-kind case series presented at ACTHIV 2025 reported that the combination of tesamorelin and GLP-1 receptor agonist therapy was highly effective in reducing both excess visceral abdominal fat and obesity in a real-world setting.
The therapeutic rationale is complementary: GLP-1 receptor agonists induce generalized weight loss in a nonspecific way, while tesamorelin selectively reduces visceral fat while preserving lean and subcutaneous tissues.
For patients whose central fat burden persists despite GLP-1 therapy, the addition of tesamorelin provides a more targeted approach to reduce visceral adiposity.
Other commonly discussed combinations include:
· Ipamorelin: The combination of tesamorelin (GHRH analogue) with Ipamorelin (selective GHS-R1a ghrelin mimetic) is a widely used stack in the research-community setting.
Tesamorelin provides pulsatile GHRH receptor activation while Ipamorelin amplifies GH pulses through a complementary receptor pathway. Research-community protocols typically use tesamorelin at 500 mcg–1 mg daily, co-administered with Ipamorelin in a fasted state.
· Retatrutide: Community reports describe a Reta/Tesa stack, combining the triple-agonist retatrutide with tesamorelin for a dual approach to appetite suppression and targeted visceral fat reduction.
· GLP-1 receptor agonists (semaglutide, tirzepatide): Stacking with GLP-1 therapies is reported to support weight loss and muscle preservation, leveraging tesamorelin's selective visceral fat reduction alongside GLP-1-mediated appetite control.
All combination approaches should be pursued under professional medical supervision.
Clinical Trial Record
Tesamorelin has been evaluated in multiple randomized controlled trials, primarily in HIV-associated lipodystrophy.
Two large placebo-controlled, double-blind Phase 3 trials demonstrated that daily injections of tesamorelin reduced visceral adiposity, preserved subcutaneous adipose tissue, improved body image and lipid levels, and were well tolerated without significantly altering glucose or insulin levels. These results formed the basis for FDA approval.
· Phase 3 trial (Falutz et al., 2010): 412 HIV-infected patients with abdominal visceral fat accumulation were randomized to tesamorelin 2 mg daily or placebo for 26 weeks. Patients receiving tesamorelin demonstrated significant visceral fat reduction and improved lipid profiles.
· Meta-analysis of 5 RCTs (2026): Confirmed significant reductions in visceral adipose tissue, trunk fat, limb fat, hepatic fat percentage, and waist circumference, with a significant increase in lean body mass.
No significant change in CD4+ T-cell counts was observed. Adverse events included arthralgia, myalgia, paresthesia, and injection-site reactions such as erythema.
· Long-term extension: The effects of tesamorelin persisted for up to 1 year of therapy, with reductions in visceral adipose tissue, lowered triglycerides, and improved C-reactive protein and carotid intimal media thickness.
· Ongoing research: A Phase 2 trial (TESA-LIVER) is evaluating tesamorelin for reducing hepatic steatosis in adults with metabolic associated steatotic liver disease (MASLD), with a primary endpoint of liver fat change at 52 weeks.
A separate trial (TRIUMPH) is investigating tesamorelin as an adjunct to exercise for improving physical function and muscle health in adults with HIV.
Tesamorelin is FDA-approved (as EGRIFTA and EGRIFTA WR) for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Technical Specifications
· Product Name: Tesamorelin 2
· Peptide: Tesamorelin (GHRH 1-44 analogue)
· Concentration: 2mg per vial
· Form: Self-mix multi-dose vial
· Reconstitution: Requires bacteriostatic water for reconstitution
· Administration: Subcutaneous injection, once daily into the abdomen
· Supplier: Test Run Wellness (Wellness.testrun)
⚕️ Important Medical Notice
Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. Tesamorelin 2 is intended for use under professional medical supervision. Tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Common adverse reactions include arthralgia, injection site reactions, peripheral edema, and myalgia.
Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.